Literature DB >> 28404107

Infliximab or ciclosporin for acute severe ulcerative colitis?

Ashwin N Ananthakrishnan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 28404107      PMCID： PMC5651678          DOI： 10.1016/S2468-1253(16)30016-4

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


× No keyword cloud information.
  9 in total

1.  Decreasing colectomy rates for ulcerative colitis: a population-based time trend study.

Authors:  Gilaad G Kaplan; Cynthia H Seow; Subrata Ghosh; Natalie Molodecky; Ali Rezaie; Gordon W Moran; Marie-Claude Proulx; James Hubbard; Anthony MacLean; Donald Buie; Remo Panaccione
Journal:  Am J Gastroenterol       Date:  2012-11-20       Impact factor: 10.864

2.  An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis.

Authors:  David J Gibson; Zaid S Heetun; Ciaran E Redmond; Kavin S Nanda; Denise Keegan; Kathryn Byrne; Hugh E Mulcahy; Garret Cullen; Glen A Doherty
Journal:  Clin Gastroenterol Hepatol       Date:  2014-07-30       Impact factor: 11.382

Review 3.  Review article: the practical management of acute severe ulcerative colitis.

Authors:  D Seah; P De Cruz
Journal:  Aliment Pharmacol Ther       Date:  2016-01-04       Impact factor: 8.171

Review 4.  Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids.

Authors:  Neeraj Narula; John K Marshall; Jean-Frederic Colombel; Grigorios I Leontiadis; John G Williams; Zack Muqtadir; Walter Reinisch
Journal:  Am J Gastroenterol       Date:  2016-02-09       Impact factor: 10.864

5.  A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations.

Authors:  Ashwin N Ananthakrishnan; Emily L McGinley; David G Binion; Kia Saeian
Journal:  J Gastrointest Surg       Date:  2010-11-25       Impact factor: 3.452

6.  Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis.

Authors:  Johannan F Brandse; Gijs R van den Brink; Manon E Wildenberg; Desiree van der Kleij; Theo Rispens; Jeroen M Jansen; Ron A Mathôt; Cyriel Y Ponsioen; Mark Löwenberg; Geert R A M D'Haens
Journal:  Gastroenterology       Date:  2015-04-25       Impact factor: 22.682

7.  Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.

Authors:  David Laharie; Arnaud Bourreille; Julien Branche; Matthieu Allez; Yoram Bouhnik; Jerome Filippi; Frank Zerbib; Guillaume Savoye; Maria Nachury; Jacques Moreau; Jean-Charles Delchier; Jacques Cosnes; Elena Ricart; Olivier Dewit; Antonio Lopez-Sanroman; Jean-Louis Dupas; Franck Carbonnel; Gilles Bommelaer; Benoit Coffin; Xavier Roblin; Gert Van Assche; Maria Esteve; Martti Färkkilä; Javier P Gisbert; Philippe Marteau; Stephane Nahon; Martine de Vos; Denis Franchimont; Jean-Yves Mary; Jean-Frederic Colombel; Marc Lémann
Journal:  Lancet       Date:  2012-10-10       Impact factor: 79.321

Review 8.  Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis.

Authors:  Shailja C Shah; Jean-Frederic Colombel; Bruce E Sands; Neeraj Narula
Journal:  Clin Gastroenterol Hepatol       Date:  2016-01-30       Impact factor: 11.382

9.  Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial.

Authors:  John G Williams; M Fasih Alam; Laith Alrubaiy; Ian Arnott; Clare Clement; David Cohen; John N Gordon; A Barney Hawthorne; Mike Hilton; Hayley A Hutchings; Aida U Jawhari; Mirella Longo; John Mansfield; Jayne M Morgan; Frances Rapport; Anne C Seagrove; Shaji Sebastian; Ian Shaw; Simon P L Travis; Alan Watkins
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.